✨ Free AI Report
Kyverna Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Kyverna Therapeutics, Inc.
Company Research

Kyverna Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Kyverna Therapeutics, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Kyverna's strong Phase 2 efficacy data and pathway to potential first-in-class CAR-T approval for autoimmune disease positions it as a significant player in an underserved market. KYV-101 achieved all primary and secondary endpoints in Phase 2 gMG trials with 100% of patients achieving rapid, robust reductions in disease markers.

What is Kyverna Therapeutics, Inc.'s industry? Kyverna Therapeutics, Inc. (kyvernatx.com) operates in Biopharmaceuticals - Cell Therapy / Immunotherapy. AskCyborg classifies Kyverna Therapeutics, Inc. under Biopharmaceuticals - Cell Therapy / Immunotherapy in its company registry.

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101, an autologous CD19 CAR T-cell therapy for stiff person syn...

8/ 10Strong

Cyborg Score thesis

Kyverna's strong Phase 2 efficacy data and pathway to potential first-in-class CAR-T approval for autoimmune disease positions it...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Cell Therapy / Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Kyverna Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Kyverna Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Kyverna Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Kyverna Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Kyverna Therapeutics, Inc. Overview

Pro stress-test →

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101, an autologous CD19 CAR T-cell therapy for stiff person syndrome, myasthenia gravis, lupus nephritis, multiple sclerosis, and systemic sclerosis. The company is pioneering a durable disease-clearing approach aiming for deep B cell depletion and an immune system reset to achieve treatment-free remission.

Strategic Profile

Pro stress-test →

Kyverna has experienced leadership from Kite Therapeutics veterans with proven CAR-T market expertise. The company maintains ample funding with cash runway extending well into 2027 without additional fundraising. The company has a license and collaboration agreement with Intellia Therapeutics to develop an allogeneic CD19 CAR T-cell product.

Competitive Landscape

Pro stress-test →

Kyverna is building presence in the biopharmaceutical landscape through innovative CAR T-cell technology, robust clinical strategy, and collaborative partnerships. Key competitors in CAR-T for autoimmune disease include Artiva Biotherapeutics, Cabaletta Bio, and other clinical-stage immunotherapy companies, though Kyverna appears positioned as a potential first-to-market for CAR-T in autoimmune indications.

Industry Context

Kyverna Therapeutics, Inc. operates in Biopharmaceuticals - Cell Therapy / Immunotherapy.

Key facts

Founded: 2018 · Headquarters: Emeryville, California · Revenue: $0 · Market cap: ~$93M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Kyverna Therapeutics, Inc..

  • Positive interim Phase 2 data in gMG demonstrated all primary and secondary endpoints with 100% of patients achieving rapid, robust disease reduction sustained through 24 weeks, positioning KYV-101 as potentially transformative therapy.
  • Landmark Phase 2 results in stiff person syndrome could enable miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease with BLA submission planned for 1H 2026.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Recent clinical update from Kyverna
  • December 2025Positive topline data from KYSA-8 Phase 2 trial in stiff person syndrome with 46% average symptom improvement
  • +1 moreTrack every material event for Kyverna Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Kyverna Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell TherapyDeveloping CAR-T therapies for autoimmune diseases→Hematopoietic Stem Cell TherapyDeveloping cell therapies for autoimmune diseases→Allogeneic CAR-T ResearchCollaboration partner for allogeneic CD19 CAR cell therapy→

Compare Kyverna Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Kyverna Therapeutics, Inc. operates in Biopharmaceuticals - Cell Therapy / Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Cell Therapy / Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Kyverna Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Kyverna Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Kyverna Therapeutics, Inc. do this quarter?”
“Is Kyverna Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Kyverna Therapeutics, Inc. do?+
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101, an autologous CD19 CAR T-cell therapy for stiff person syn...
What is Kyverna Therapeutics, Inc.'s Cyborg Score?+
Kyverna Therapeutics, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Kyverna Therapeutics, Inc.'s main competitors?+
Named competitors include CAR-T Cell Therapy, Hematopoietic Stem Cell Therapy, Allogeneic CAR-T Research. The full competitive landscape is in the AskCyborg report.
How can I get the full Kyverna Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Kyverna Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Kyverna Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.